New perspectives in the treatment of allergic rhinitis and asthma in children

Current Opinion in Allergy and Clinical Immunology

Volumn 7, Issue 2, 2007, Pages 201-206

  Baena Cagnani, Carlos E ^a   Passalacqua, Giovanni ^b   Gómez, Maximiliano ^c   Zernotti, Mario E ^d   Canonica, G Walter ^b  

^a UNIVERSIDAD CATÓLICA DE CÓRDOBA   (Argentina)

^b UNIVERSITY OF GENOA   (Italy)

^c Alas Medical Centre   (Argentina)

^d UNIVERSIDAD NACIONAL DE CÓRDOBA   (Argentina)

Author keywords

Allergic diseases; Children; Ciclesonide; Omalizumab; Specific sublingual immunotherapy

Indexed keywords

ANTIHISTAMINIC AGENT; BUDESONIDE; CICLESONIDE; CORTICOSTEROID; CYTOKINE; FLUTICASONE; IMMUNOGLOBULIN E; IMMUNOGLOBULIN E ANTIBODY; MONOCLONAL ANTIBODY; NEDOCROMIL; OMALIZUMAB; PLACEBO; STEROID;

ADVERSE OUTCOME; ALLERGIC RHINITIS; ASTHMA; CHRONIC DISEASE; CLINICAL TRIAL; DISEASE CONTROL; DISEASE COURSE; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EMERGENCY CARE; FIRST PASS EFFECT; HOSPITALIZATION; HUMAN; HYPOTHALAMUS HYPOPHYSIS SYSTEM; IMMUNOTHERAPY; LUNG FUNCTION; PEAK EXPIRATORY FLOW; PREVALENCE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; T LYMPHOCYTE;

ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL; ASTHMA; CHILD; CHILD, PRESCHOOL; HUMANS; IMMUNOTHERAPY; MIDDLE AGED; RHINITIS, ALLERGIC, PERENNIAL;

EID: 33947126891     PISSN: 15284050     EISSN: 14736322     Source Type: Journal    
DOI: 10.1097/ACI.0b013e3280895d36     Document Type: Review

References (51)

1. Asher MI, Montefort S, Bjorkstén B, et al. Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC phases one and three repeat multicountry cross-sectional surveys. Lancet 2006; 368:733-743. A reference paper for prevalence trends in allergic diseases worldwide.
2. Holgate S, Casale T, Wenzel S, et al. The anti-inflammatory effects of omalizumab confirm the central role of IgE in allergic inflammation. J Allergy Clin Immunol 2005; 115:459-465.
3. GINA: Global Initiative for Asthma. Global strategy for asthma management and prevention, 2006; Available at: www.ginasthma.org. Accessed: January 2006. Top guidelines for the diagnosis and management of asthma.
4. Bateman ED, Boushey HA, Bousquet J, et al. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma Control study. Am J Respir Crit Care Med 2004; 170:836-844.
5. Rabe KF, Adachi M, Lai CK, et al. Worldwide severity and control of asthma in children and adults: the global asthma insights and reality surveys. J Allergy Clin Immunol 2004; 114:40-47.
6. Price D, Thomas M. Breaking new ground: challenging existing asthma guideliness. BMC Pulm Med 2006; 6 (Suppl 1):S6.
7. Asher MI, Montefort S, Bjorksten B, et al., ISAAC Phase Three Study Group. Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC phases one and three repeat multicountry cross-sectional surveys. Lancet 2006; 368:733-743.
8. ARIA: Allergic rhinitis and its impact on asthma. ARIA Workshop Report. J Allergy Clin Immunol 2001; 108 (5 Suppl): 1-205.
9. Galassi C, De Sario M, Biggeri A, et al. Changes in prevalence of asthma and allergies among children and adolescents in Italy: 1994-2002. Pediatrics 2006; 117:34-42.
10. Linneberg A. Changes in atopy over 25 years: allergy epidemic has spread to old age. BMJ 2005; 331:352.
11. Meltzer EO. Allergic rhinitis: managing the paediatric spectrum. Allergy Asthma Proc 2006; 27:2-8. An interesting analysis of the therapeutic concerns in allergic rhinitis in children.
12. Roehr CC, Forster J. Are topical corticosteroids superior to systemic histamine antagonists in treatment of allergic seasonal rhinitis? Arch Dis Child 2002; 87:412-413.
13. Meltzer EO, Derendorf H. The systemic safety of inhaled corticosteroid therapy: a focus on ciclesonide. Ann Allergy Asthma Immunol 2006; 97:149-157. Useful revision to become familiar with the new inhaled corticosteroid, ciclesonide.
14. Gelfand EW, Georgitis JW, Noonan M, Ruff ME. Once-daily ciclesonide in children: efficacy and safety in asthma. J Pediatr 2006; 148:377-383. A recommended analysis for the main concern about a new inhaled corticosteroid, in a special population such as children.
15. Holgate S, Djukanovic R, Casale T, Bousquet J. Antiimmunoglobulin E treatment with omalizumab in allergic diseases: an update on anti-inflammatory activity and clinical efficacy. Clin Exp Allergy 2005; 35:408-416.
16. Bousquet J, Lockey R, Malling H. WHO Position Paper. Allergen immunotherapy: therapeutic vaccines for allergic diseases. Allergy 1998; 53 (Suppl 44): 1-42.
17. Baena-Cagnani CE, Passalacqua G, Baena-Cagnani R, et al. Sublingual immunotherapy in pediatric patients: beyond clinical efficacy. Curr Opin Allergy Clin Immunol 2005; 5:173-177.
18. Penagos M, Compalati E, Tarantini F, Baena-Cagnani R, et al. Efficacy of sublingual immunotherapy in the treatment of allergic rhinitis in pediatric patients 3 to 18 years of age: a meta-analysis of randomized, placebo-controlled, double-blind trials. Ann Allergy Asthma Immunol 2006; 97:141-148. A meta-analysis of the efficacy of SLIT in allergic rhinitis in children.
19. Rizzo MCV, Sole D. Inhaled corticosteroids in the treatment of respiratory allergy: safety vs efficacy. J Pediatr (Rio J) 2006; 82 (5 Suppl):S198-S205. Excellent revision on topical steroids, everything we need to remember.
20. Szefler S, Weiss S, Tonascia A, and The Childhood Asthma Management Program Research Group (CAMP). Long term effects of budesonide or nedocromil in children with asthma. N Engl J Med 2000; 343:1054-1063.
21. Agertoft L, Pedersen S. Effect of long-term treatment with inhaled budesonide on adult height in children with asthma. N Engl J Med 2000; 343:1064-1069.
22. Colice GL. The newly developed inhaled corticosteroid ciclesonide for the treatment of asthma. Expert Opin Pharmacother 2006; 7:2107-2117.
23. Ukena D, Biberger C, Steinijans V, et al. Ciclesonide is more effective than budesonide in the treatment of persistent asthma. Pulm Pharmacol Ther 11 July 2006; e-pub ahead of press.
24. Pedersen S, García García ML, Manjra A, et al. A comparative study of inhaled ciclesonide 160 microg/day and fluticasone propionate 178 microg/day in children with asthma. Pediatric Pulmonol 2006; 41:954-961.
25. Lee DK, Fardon TC, Bates CE, et al. Airway and systemic effects of hydro-fluoroalkane formulations of high dose ciclesonide and fluticasone in moderate persistent asthma. Chest 2005; 127:851-860.
26. Ratner PH, Wingertzahn MA, van Bavel JH, et al. Effectiveness of ciclesonide nasal spray in the treatment of seasonal allergic rhinitis. Ann Allergy Asthma Immunol 2006; 97:657-663.
27. Ratner PH, Wingertzahn MA, van Bavel JH, et al. Efficacy and safety of ciclesonide nasal spray for the treatment of seasonal allergic rhinitis. J Allergy Clin Immunol 2006; 118:1142-1148.
28. Corne J, Djukanovitch R, Thomas L, et al. The effect of intravenous administration of chimeric anti IgE antibody on serum IgE levels in atopic subjects. Efficacy, safety and pharmacokinetics. J Clin Invest 1997; 99:879-887.
29. Vignola AM, Humbert M, Bousquet J, et al. Efficacy and tolerability of antiimmunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR. Allergy 2004; 59:709-717.
30. Bousquet J, Cabrera P, Berkman N, et al. The effect of treatment with omalizumab, an anti IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma. Allergy 2005; 60:302-308.
31. Soler M, Matz J, Townley R, et al. The anti IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J 2001; 18:254-261.
32. Busse W, Corren J, Lanier BQ, et al. Omalizumab, anti IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol 2001; 108:184-190.
33. Milgrom H, Berger W, Nayak A, et al. Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab). Pediatrics 2001; 108:e36.
34. Bousquet J, van Cauwenberge P, Ait Khaled N, et al. Pharmacologic and anti-IgE treatment of allergic rhinitis. ARIA update (in collaboration with GA2LEN). Allergy 2006; 61:1086-1096. An update of ARIA treatment as there was scarce experience with anti-IgE at the time the guideline was released.
35. Chervinsky P, Casale T, Townley R, et al. Omalizumab, an anti-IgE antibody, in the treatment of adults and adolescents with perennial allergic rhinitis. Ann Allergy Asthma Immunol 2003; 91:160-167.
36. Casale TB, Condemi J, LaForce C, et al. Effect of omalizumab on symptoms of seasonal allergic rhinitis: a randomized controlled trial. JAMA 2001; 286:2956-2967.
37. D'Amato G, Bucchioni E, Oldani V, Canonica W. Treating moderate-to-severe allergic asthma with a recombinant humanized anti-IgE monoclonal antibody (omalizumab). Treat Respir Med 2006; 5:393-398.
38. Abramson MJ, Puy RM, Weiner JM. Allergen immunotherapy for asthma. Cochrane Database Syst Rev 2003; (4): CD001186.
39. Kuehr J, Brauburger J, Zielen S, et al. Efficacy of combination treatment with anti-IgE plus specific immunotherapy in polysensitized children and adolescents with seasonal allergic rhinitis. J Allergy Clin Immunol 2002; 109:274-280.
40. Passalacqua G, Canonica GW. Sublingual immuntherapy: update 2006. Curr Opin Allergy Clin Immunol 2006; 6:449-454.
41. Passalacqua G, Baena-Cagnani CE, Berardi M, Canonica GW. Oral and sublingual immunotherapy in paediatric patients. Curr Opin Allergy Clin Immunol 2003; 3:139-145.
42. Pajno GB, Peroni DG, Vita D, et al. Safety of sublingual immunotherapy in children with asthma. Paediatr Drugs 2003; 5:777-781.
43. Fiocchi A, Pajno G, La Grutta S, et al. Safety of sublingual-swallow immunotherapy in children aged 3 to 7 years. Ann Allergy Asthma Immunol 2005; 95:254-258.
44. Di Rienzo V, Minelli M, Musarra A, et al. Postmarketing survey on the safety of sublingual immunotherapy in children below the age of 5 years. Clin Exp Allergy 2005; 35:560-564.
45. Akdis CA, Barlan IB, Bahceciler N, Akdis M. Immunological mechanisms of sublingual immunotherapy. Allergy 2006; 61 (Suppl 81):11-14.
46. Cosmi L, Santarlasci V, Angeli R, et al. Sublingual immunotherapy with Dermatophagoides monomeric allergoid down-regulates allergen-specific immunoglobulin E and increases both interferon-gamma and interleukin-10 production. Clin Exp Allergy 2006; 36:261-272.
47. Miceli Sopo S, Macchiaiolo M, Zorzi G, Tripodi S. Sublingual immunotherapy in asthma and rhinoconjunctivitis; systematic review of paediatric literature. Arch Dis Child 2004; 89:620-624.
48. Calamita Z, Saconato H, Pela AB, Atallah AN. Efficacy of sublingual immunotherapy in asthma: systematic review of randomized clinical trials using the Cochrane Collaboration method. Allergy 2006; 61:1162-1172. A description showing that the evaluation of outcomes and measurements needs to be more homogeneous; however, it is still in favour of SLIT.
49. Wilson DR, Torres Lima M, Durham SR. Sublingual immunotherapy for allergic rhinitis: systematic review and meta-analysis. Allergy 2005; 60:4-12.
50. Novembre E, Galli E, Landi F, et al. Coseasonal sublingual immunotherapy reduces the development of asthma in children with allergic rhinoconjunctivitis. J Allergy Clin Immunol 2004; 114:851-857.
51. Guilbert TW, Morgan WJ, Zeiger RS, et al. Long-term inhaled corticosteroids in preschool children at high risk for asthma. N Engl J Med 2006; 354:1985-1997. An interesting evaluation concluding that inhaled corticosteroids cannot modify the natural course of asthma development.